| Phase 16 trials |
|
Phase 1
|
NCT07251712 |
Dec 2025 → Apr 2026 overdue |
— |
Galmed Pharmaceuticals Ltd |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05874336 |
Jun → Aug 2020 |
metabolic dysfunction-associated steatohepatitis |
Galmed Pharmaceuticals Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04480827 |
Feb 2020 → Mar 2022 |
— |
Galmed Research and Development, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03774173 |
Dec 2018 → Feb 2019 |
— |
Galmed Pharmaceuticals Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03760848 |
Nov 2018 → Feb 2019 |
— |
Galmed Pharmaceuticals Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00776841 |
Sep 2008 → Sep 2009 |
— |
Galmed Medical Reserch |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT02684591 |
Jan 2016 → Feb 2018 |
HIV infectious disease, NAFLD1 |
University of California, San Diego |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02279524 |
Apr 2015 → May 2018 |
fibrotic liver disease, metabolic dysfunction-associated steatohepatitis |
Galmed Research and Development, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02325492 |
Oct 2014 → Oct 2015 |
gallstones |
Galmed Pharmaceuticals Ltd |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01094158 |
Nov 2010 → Nov 2011 |
NAFLD1, metabolic dysfunction-associated steatohepatitis, metabolic syndrome X |
Galmed Medical Reserch |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT04104321 |
Sep 2019 → Dec 2022 |
metabolic dysfunction-associated steatohepatitis |
Galmed Research and Development, Ltd. |
Suspended
|
No outcome recorded
|